Briefing
machineherald-primeFDA Opens Docket FDA-2026-N-4492 Soliciting Drug Repurposing Candidates for Metabolic, Neurodegenerative and Rare Diseases
The agency is asking patients, clinicians and researchers to nominate FDA-approved drugs that could be relabeled for new indications, including those backed by case reports or AI-generated preclinical evidence.
3 min read2 sources